Keyphrases
Surabaya
74%
AIDS/HIV
68%
Indonesia
63%
COVID-19
29%
Pseudomonas Aeruginosa (P. aeruginosa)
25%
Tuberculosis
25%
AIDS Patients
23%
Human Immunodeficiency Virus Type 1 (HIV-1)
22%
HIV Patients
20%
Candida Albicans (C. albicans)
20%
Drug Resistance mutations
20%
Cryptococcal Meningitis
18%
Polymicrobial Biofilm
18%
Lactobacillus Acidophilus
18%
Sepsis Severity
18%
Lymphocytes
18%
Robusta Coffee
18%
Human Immunodeficiency Virus Drug Resistance
18%
Human Immunodeficiency Virus/acquired Immunodeficiency Syndrome
18%
People Living with HIV (PLHIV)
18%
Lampung
16%
Coffee Extract
16%
Nave
15%
Sepsis Patients
14%
CRF01_AE
14%
Fever
14%
Platelet Count
14%
Brain Edema
12%
Immunodeficiency Virus
12%
Anti-tuberculosis Therapy
12%
Clinical Signs
12%
Fixed-dose Combination
12%
Rare Manifestation
12%
Meropenem
12%
Zidovudine
12%
Gram-negative Bacteria
11%
Biofilm
11%
Hemoglobin Level
11%
Dengue Fever
11%
HIV Infection
11%
Type 1 Diabetes Mellitus (T1DM)
11%
Diabetic Patients
11%
CD4 Count
11%
Clinical Specimens
10%
CD4 Level
10%
Academic Hospital
10%
Clinical Characteristics
10%
Tenofovir
10%
Immature Platelets
10%
High Prevalence
10%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Diseases
51%
Pseudomonas aeruginosa
29%
Drug Resistance
29%
Prevalence
29%
Human Immunodeficiency Virus 1
24%
Human Immunodeficiency Virus Infection
23%
Infection
23%
Acquired Immune Deficiency Syndrome
23%
Candida Albicans
18%
Dengue Virus
18%
Meningoencephalitis
18%
Sepsis
18%
Coffea Canephora
18%
Coronavirinae
15%
Dengue
14%
Diabetes Mellitus
13%
Brain Edema
12%
Immune Deficiency
12%
Lactobacillus acidophilus
11%
Meropenem
11%
Virus Infection
11%
SARS Coronavirus
10%
Disease Severity
10%
Antimicrobial Resistance
10%
Cohort Study
10%
Tenofovir
10%
Zidovudine
10%
Cross-Sectional Study
10%
Gram Negative Bacterium
10%
Inflammation
9%
Mortality Rate
9%
Synergism
9%
CD4 Antigen
9%
Ileum
9%
Combination Drug
9%
Fluconazole
9%
Candida Glabrata
9%
Candida Parapsilosis
9%
Candida Tropicalis
9%
Pichia kudriavzevii
9%
Ocular Toxoplasmosis
9%
Shigella flexneri
9%
Integrase
9%
Glasgow Coma Scale
9%
Menstruation Disorder
9%
Combination Therapy
9%
Tuberculous Peritonitis
9%
Toxic Hepatitis
9%
Tuberculostatic Agent
9%
Medicine and Dentistry
Human Immunodeficiency Virus
48%
COVID-19
24%
Acquired Immune Deficiency Syndrome
22%
Virus
21%
Meningoencephalitis
18%
Human Immunodeficiency Virus Infection
17%
Prevalence
16%
Human Immunodeficiency Virus 1
14%
Diseases
13%
Infection
12%
Brain Edema
12%
Dengue Fever
12%
Immune Deficiency
12%
Platelet
11%
Mixed Infection
10%
Virus Infection
10%
Gram-Negative Bacteria
10%
Dengue Virus
9%
Antibiotic Resistance
9%
Odynophagia
9%
Tetralogy of Fallot
9%
Ocular Toxoplasmosis
9%
Cross Sectional Study
9%
Idiopathic Thrombocytopenic Purpura
9%
RNA
9%
SARS Coronavirus
9%
Disease Severity
9%
Hematocrit
9%
Antibiotic Therapy
9%
CD4 Antigen
9%
Pulmonary Infiltrate
9%
Pancreatic Tuberculosis
9%
Epileptic Seizure
9%
Tuberculous Peritonitis
9%
Tuberculostatic Agent
9%
Menstruation Disorder
9%
Secondary Syphilis
9%
Plasmodium Vivax Malaria
9%
Sepsis
9%
Toxic Hepatitis
9%
Diagnosis
9%
Procalcitonin
9%
Drug Resistance
9%
Lymphocyte
9%
Sex Worker
9%
Neutrophil
9%
Cohort Study
9%
Headache
9%
Comorbidity
8%
Septic Shock
7%